Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ANIXNASDAQ:APLTNASDAQ:ATNFNASDAQ:KZIAOTCMKTS:XYNO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.23+3.2%$3.94$2.75▼$6.45$99.85M0.85156,850 shs52,698 shsAPLTApplied Therapeutics$6.85+2.7%$4.84$0.76▼$9.39$725.35M1.822.23 million shs675,433 shsATNF180 Life Sciences$2.01+2.6%$3.64$1.80▼$51.30$771K0.47106,179 shs206,476 shsKZIAKazia Therapeutics$0.31$0.28$0.19▼$1.68$5.13M2.09843,792 shs295,045 shsXYNOXynomic Pharmaceuticals$2.22$2.22$0.20▼$3.84N/AN/AN/AN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences+3.19%-13.40%-6.10%-16.97%-28.85%APLTApplied Therapeutics+2.70%-0.72%+29.25%+120.97%+735.37%ATNF180 Life Sciences+1.52%-39.27%-46.44%-49.86%-94.25%KZIAKazia Therapeutics-0.60%+12.44%+5.69%-30.29%-68.31%XYNOXynomic Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIXAnixa Biosciences2.9218 of 5 stars3.54.00.00.02.53.30.0APLTApplied Therapeutics4.9713 of 5 stars4.55.00.04.73.33.30.6ATNF180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AKZIAKazia Therapeutics3.1868 of 5 stars3.55.00.00.03.20.01.3XYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences3.00Buy$12.00271.52% UpsideAPLTApplied Therapeutics3.00Buy$11.6069.34% UpsideATNF180 Life SciencesN/AN/AN/AN/AKZIAKazia Therapeutics3.00Buy$2.00537.55% UpsideXYNOXynomic PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest APLT, ATNF, KZIA, ANIX, and XYNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2024APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.003/21/2024ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.003/15/2024APLTApplied TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/6/2024APLTApplied TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $12.002/22/2024APLTApplied TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/22/2024APLTApplied TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.002/16/2024APLTApplied TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $7.002/13/2024ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K490.65N/AN/A$0.74 per share4.36APLTApplied Therapeutics$9.99M72.61N/AN/A($0.20) per share-34.25ATNF180 Life SciencesN/AN/A$67.00 per share0.03$57.56 per shareN/AKZIAKazia Therapeutics$20K256.29N/AN/A$0.50 per share0.63XYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$9.81M-$0.34N/AN/AN/AN/A-44.09%-40.90%6/12/2024 (Estimated)APLTApplied Therapeutics-$119.76M-$1.35N/AN/AN/AN/A-5,544.59%-275.83%5/9/2024 (Estimated)ATNF180 Life Sciences-$38.73MN/A0.00∞N/AN/A-501.18%-236.01%5/20/2024 (Estimated)KZIAKazia Therapeutics-$13.78MN/A0.00N/AN/AN/AN/AN/AN/AXYNOXynomic PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ALatest APLT, ATNF, KZIA, ANIX, and XYNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2024Q1 2024ANIXAnixa Biosciences-$0.09-$0.10-$0.01-$0.10N/AN/A3/6/2024Q4 2023APLTApplied Therapeutics-$0.15-$0.33-$0.18-$0.33N/A($0.67) million1/16/2024Q4 2023ANIXAnixa Biosciences-$0.09-$0.09N/A-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AAPLTApplied TherapeuticsN/AN/AN/AN/AN/AATNF180 Life SciencesN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/AXYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A15.1915.19APLTApplied TherapeuticsN/A0.760.76ATNF180 Life SciencesN/A0.700.70KZIAKazia TherapeuticsN/A1.421.42XYNOXynomic PharmaceuticalsN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%APLTApplied Therapeutics98.31%ATNF180 Life Sciences4.07%KZIAKazia Therapeutics30.89%XYNOXynomic PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences22.60%APLTApplied Therapeutics19.10%ATNF180 Life Sciences4.10%KZIAKazia Therapeutics1.00%XYNOXynomic Pharmaceuticals86.29%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences431.90 million24.69 millionOptionableAPLTApplied Therapeutics25105.89 million85.66 millionOptionableATNF180 Life Sciences5393,000377,000No DataKZIAKazia Therapeutics2,02116.34 million16.18 millionOptionableXYNOXynomic Pharmaceuticals27N/AN/ANot OptionableAPLT, ATNF, KZIA, ANIX, and XYNO HeadlinesSourceHeadlineWatson Pharmaceuticalsforbes.com - February 21 at 10:13 PMElite Pharmaceuticals Inc.wsj.com - February 14 at 12:30 PMHDAC Inhibitor Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightfinance.yahoo.com - January 8 at 3:26 PMFennec Pharmaceuticals Inc FENCmorningstar.com - November 1 at 1:58 AMStarfield:Pharmaceuticalsvideogamer.com - September 26 at 5:59 PMDelveInsight Highlights Major Advances, Transformative Therapies, and 195+ Leading Players Wheeling the Glioblastoma Clinical Trial Pipeline Landscapebenzinga.com - September 1 at 8:35 PMGlaxosmithkline Pharmaceuticalslivemint.com - July 8 at 4:16 PMCompany History - Paam Pharmaceuticalsmoneycontrol.com - May 30 at 7:13 AMGlenmark Pharmaceuticals Get USFDA Nod For Human Trial Of Advanced Cancer-Treating Drugoutlookindia.com - March 18 at 3:41 PMDelveInsight Evaluates a Robust High-grade Glioma Pipeline as 120+ Influential Pharma Players to Set Foot in the Domainfinance.yahoo.com - March 13 at 6:05 PMPharmaceutical Secondary Packaging Equipment Market 2022 Key Product Segments, Application Analysis, and Industry Growth Forecast by 2028marketwatch.com - October 7 at 12:35 AMP53 Antagonist Shows Early Activity in Advanced Liposarcomamedpagetoday.com - June 8 at 9:53 PMSelinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trialascopubs.org - April 10 at 9:25 AMFollicular Lymphoma Market to Witness Expansion at a 6.85% CAGR during the Study Period [2018-2030], States DelveInsightfinance.yahoo.com - February 9 at 12:55 PMXynomic Pharmaceuticals Holdings Inc (XYNO)investing.com - January 5 at 10:07 PMFollicular Lymphoma Market Size 2021: CAGR Value, Top Manufacturers, Industry Share, Growth, Supply Demand and Forecast till 2026wboc.com - November 10 at 7:29 PMFollicular Lymphoma Drug Landscape Report 2021 - ResearchAndMarkets.comnz.finance.yahoo.com - August 7 at 7:01 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAnixa BiosciencesNASDAQ:ANIXAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Applied TherapeuticsNASDAQ:APLTApplied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.180 Life SciencesNASDAQ:ATNF180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Kazia TherapeuticsNASDAQ:KZIAKazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.Xynomic PharmaceuticalsOTCMKTS:XYNOXynomic Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma or R/R diffuse large b-cell lymphoma (DLBCL); and XYN-604, which is in phase 1b trial for treatment of multiple solid tumors. It also develops single agent monotherapy products that is in phase II clinical trial, including XYN-601 for treatment of R/R follicular lymphoma (FL); XYN-606 to treat R/R DLBCL; and XYN-605 for treatment of R/R FL. In addition, the company develops drug candidate XP-105, a mTORC1/2 inhibitor, which has completed Phase I clinical trial for treatment of breast cancer. Further, its pre-clinical oncology drug candidate include XP-102 (BI 882370), a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.